Author(s): Tamilisetti Vidya Sagar, Yatish Byndoor, Anupam Das

Email(s): Email ID Not Available

DOI: 10.52711/0974-360X.2022.00372   

Address: Tamilisetti Vidya Sagar, Yatish Byndoor, Anupam Das
Department of Pharmacology, GSL Medical College, Rajahmundry, AP 533294.
*Corresponding Author

Published In:   Volume - 15,      Issue - 5,     Year - 2022


ABSTRACT:
Objective: The Purpose of this study is to evaluate prescribing pattern of drugs to prevent progression of nephropathy in patients of diabetes in a tertiary care hospital. Materials and Methods: It was conducted in a tertiary care hospital, written informed consent was taken from those patients, who fulfilled study criteria and study sample included type 2 diabetic nephropathy outdoor patients who aged more than 40 years who were in stage of micro albuminuria (stage 3 diabetic nephropathy), details like sex, duration of illness, on-going treatment concurrent medicines were recorded in predesigned and pretested case record forms, these data were subjected to analysis using descriptive methods, Microsoft excel was used for data entry and descriptive analysis. A total of 100 patients were included in the study. A written permission has been obtained from Institutional Ethics Committee for the conduct of the study. Results: In the present study there were 100 patients, of whom 63 were males and 37 were females, majority of patients have diabetes for more than 20 years, all patients received anti-hypertensive, anti-diabetic and hypolipidaemic drugs. Among antihypertensive drugs, ACE inhibitors are prescribed most followed by diuretics and calcium channel blockers, among ACE inhibitors; Enalapril and Ramipril were prescribed most. Insulin was prescribed in 50% of patients and Glimepiride was the most common sulfonylurea prescribed. Statins were prescribed most among hypolipidaemic drugs; orlistat was prescribed only for 5% of patients. Majority of the patients were advised by physician regarding regular exercise, protein restricted diet, salt restriction, avoidance of cigarette smoking and weight reduction. Conclusion: Our study concluded that prescribing pattern of drugs in diabetic nephropathy was as per current practices and recommendations of guidelines. The pattern of drug use was to achieve better control of all the risk factors which are involved in progression of nephropathy. Further large scale and more detailed study, which includes sample from government setup and private clinics, is recommended to confirm our findings


Cite this article:
Tamilisetti Vidya Sagar, Yatish Byndoor, Anupam Das. Prescribing pattern of Antihypertensive, Anti-Diabetic, Hypolipidaemic and Anti-Obesity Drugs in Diabetic Nephropathy. Research Journal of Pharmacy and Technology. 2022; 15(5):2240-3. doi: 10.52711/0974-360X.2022.00372

Cite(Electronic):
Tamilisetti Vidya Sagar, Yatish Byndoor, Anupam Das. Prescribing pattern of Antihypertensive, Anti-Diabetic, Hypolipidaemic and Anti-Obesity Drugs in Diabetic Nephropathy. Research Journal of Pharmacy and Technology. 2022; 15(5):2240-3. doi: 10.52711/0974-360X.2022.00372   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-5-54


REFERENCES:
1.    Ranjith Unnikrishnan, Mohan Rema, Rajendra Pradeepa M, Mohan Deepa M. Prevalence and Risk Factors of Diabetic Nephropathy in an Urban South Indian. The Chennai Urban Rural Epidemiology Study (CURES 45) Blood Pressure. 2007;30(8):2019-24.  10.2337/dc06-2554
2.    Gerstein HC, Mann JFE, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators: Albuminuria and risk of CV events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 286: 421–426, 2001. 10.1001/jama.286.4.421
3.    Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157: 1413–1418, 1997. 10.1001/archinte.1997.00440340025002
4.    Borch-Johnsen K, Andersen PK, Deckert T: The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28: 590–596, 1985. https://doi.org/10.1007/BF00281993
5.    Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G: Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41: 736–741, 1992. 10.1136/qhc.9.4.257
6.    Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44: 1303–1309, 1995. 10.1136/qhc.9.4.257
7.    Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC: Effect of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. BMJ 329: 828– 831, 2004. https://doi.org/10.1136/bmj.38237.585000.7C
8.    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Com-mittee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289: 2560–2572, 2003. 10.1001/jama.289.19.2560
9.    K-DOQI Clinical Practice Guidelines on Blood Pressure Management and Use of Antihypertensive Agents in Chronic Kidney Disease. Executive Summary, October 2003. Available: http://www.kidney.org. Accessed August 3, 2004
10.    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee: Nephropathy. Available: http:// mdm.ca/cpgsnew/cpgs/search/english/results.asp. Accessed August 3, 2004
11.    2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011–1053, 2003. 10.1097/01.hjh.0000059051.65882.32
12.    Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM; BHS guidelines working party, for the British Hypertension Society: British
13.    Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary. BMJ 328: 634–640, 2004. 10.1136/bmj.328.7440.634
14.    Caring for Australians with Renal Impairment Guidelines. Available: http://www.kidney.org.au/cari/drafts/new/ prevention.html. Accessed August 3, 2004 w
15.    Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, et al. The Relationship between Proteinuria and Coronary Risk : A Systematic Review and meta-analysis. PLoS Medicine. 2008;5(10):1486-95. https://doi.org/10.1371/journal.pmed.0050207
16.    G.H. Rimoy, M. Justin-Temu and C. Nilay. Prescribing Patterns and Cost of Antihypertensive Drugs in Private Hospitals in Dares Salaam, Tanzania. East and Central African Journal of Pharmaceutical Sciences 2008; 11:69-73. 10.4314/ecajps.v11i3.46285
17.    Joseph N, Yogananda R, Bharathi DR, Padman V, Sandeep GN. A study on prescription pattern of antihypertensive agents in chronic renal failure patients and assessment of medication adherence. Int J Pharm Sci Rev Res 2017;45(2):72-5. http://dx.doi.org/10.18203/2319-2003.ijbcp20211015
18.    Dahal P, Maharjan L, Dahal B, Gupta K. Assessment of prescription patterns in hypertensive and diabetic patients visiting private tertiary care hospital of Dharan Municipality, Nepal. Sunsari Technical College Journal. 2015;2(1):44-7. http://dx.doi.org/10.18203/2319-2003.ijbcp20180486
19.    Kamrai D, Sachdeva P. Prescribing Trends of Antidiabetics In Diabetic Patients And Hypertensive Diabetic Patients In An Urban Secondary Care Hospital. Int J Pharm Biol Arch. 2010;1(2):249-55.  http://dx.doi.org/10.18203/2319-2003.ijbcp20181183
20.    Rekha MB, Rekha MS, Purushotham N. A Study of Prescribing Pattern in Type-2 Diabetics with Co-Existing Hypertension. Indian Journal of Public Health Research and Development. 2014;5(1):28-33. 10.5958/j.0976-5506.5.1.008
21.    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9. 10.1056/NEJMoa011161
22.    Flack JM. Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan / hydrochlorothiazide. Int J Clin Pract,. 2007 ;61(12):2093-102. 10.1111/j.1742-1241.2007.01577.x

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available